Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifampin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 2/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifampin SCHEMBL14922822 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14029509 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL13230041 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14405975 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14927261 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL1176203 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL19457678 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL23490 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL22517710 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL22432205 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20230414584-A1 | ADMINISTRATION OF ANTIBIOTIC COMPOUNDS FOR THE TREATMENT OF STREPTOCOCCAL INFECTIONS FOR THE TREATMENT OF PSORIASIS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2023-12-28 | — | — | US | claimed |
| US-20230404983-A1 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING OBSESSIVE-COMPULSIVE DISORDER | CENTRE FOR DIGESTIVE DISEASES (AU) | 2023-12-21 | — | — | US | claimed |
| CN-116650492-A | Administration of antibiotic compounds for the treatment of streptococcal infections to treat psoriasis | 消化系统疾病中心 | 2023-08-29 | — | — | CN | claimed |
| EP-3955927-A1 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING AND PREVENTING H. PYLORI INFECTIONS | Borody, Thomas Julius (AU) | 2022-02-23 | — | — | EP | claimed |
| US-20220040156-A1 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING OBSESSIVE-COMPULSIVE DISORDER | CENTRE FOR DIGESTIVE DISEASES (AU) | 2022-02-10 | — | — | US | claimed |
| CN-113939293-A | Compositions and methods for treating, ameliorating and preventing helicobacter pylori infection | 托马斯·朱利叶斯·波洛迪 | 2022-01-14 | — | — | CN | claimed |
| EP-3768262-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE AND FUSOBACTERIA-CAUSED OR RELATED DISEASES AND CONDITIONS | Borody, Thomas Julius (AU) | 2021-01-27 | — | — | EP | claimed |
| US-20210000806-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE AND FUSOBACTERIA-CAUSED OR RELATED DISEASES AND CONDITIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2021-01-07 | — | — | US | claimed |
| CN-112165943-A | Compositions and methods for treating diseases and conditions caused by or associated with inflammatory bowel disease and fusobacteriales | 托马斯·朱利叶斯·波洛迪 | 2021-01-01 | — | — | CN | claimed |
| WO-2007089907-A2 | CATIONIC STEROID ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | BRIGHAM YOUNG UNIVERSITY (US) | 2007-08-09 | — | — | WO | claimed |
| WO-2007089906-A2 | CATIONIC STEROID ANTIMICROBIAL COMPOSITIONS FOR TREATING OR PREVENTING HERPES INFECTIONS | BRIGHAM YOUNG UNIVERSITY (US) | 2007-08-09 | — | — | WO | claimed |
| US-7115640-B2 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2006-10-03 | — | — | US | claimed |
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. | 2004-09-16 | — | — | US | claimed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | claimed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| JP-2665399-B2 | — | — | 1997-10-22 | — | — | JP | claimed |
| EP-0633795-A4 | ANTIBACTERIAL COATED MEDICAL IMPLANTS. | UNIV TEXAS (US) | 1995-05-24 | — | — | EP | claimed |
| EP-0633795-A1 | ANTIBACTERIAL COATED MEDICAL IMPLANTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-01-18 | — | — | EP | claimed |
| WO-1993017746-A1 | ANTIBACTERIAL COATED MEDICAL IMPLANTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-09-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | IL1B, IL5, SERPINB1 | MAPT 2458/4885NR1I2 3142/4885ABCB11 510/4885 |
| US-20210000806-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE AND FUSOBACTERIA-CAUSED OR RELATED DISEASES AND CONDITIONS | APC, FBL, NOD2 | MAPT 451/4885NR1I2 2364/4885ABCB11 614/4885 |
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | MAPT 4111/4885NR1I2 4/4885ABCB11 568/4885 |
| US-20230404983-A1 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING OBSESSIVE-COMPULSIVE DISORDER | SFXN1, SFXN3, GRIN2D | MAPT 3676/4885NR1I2 432/4885ABCB11 1800/4885 |
| US-20220040156-A1 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING OBSESSIVE-COMPULSIVE DISORDER | SFXN1, SFXN3, GRIN2D | MAPT 3676/4885NR1I2 432/4885ABCB11 1800/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | MAPT 2169/4885NR1I2 1552/4885ABCB11 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.